DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A
DEB025/Debio 025 (Alisporivir) is a cyclophilin (Cyp)-binding molecule with potent anti-hepatitis C virus (HCV) activity both in vitro and in vivo. It is currently being evaluated in phase II clinical trials. DEB025 binds to CypA, a peptidyl-prolyl cis-trans isomerase which is a crucial cofactor for...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
October 27, 2010
|
| In: |
PLOS ONE
Year: 2010, Jahrgang: 5, Heft: 10, Pages: 1-14 |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0013687 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1371/journal.pone.0013687
|
| Verfasserangaben: | Lotte Coelmont, Xavier Hanoulle, Udayan Chatterji, Carola Berger, Joke Snoeck, Michael Bobardt, Precious Lim, Inge Vliegen, Jan Paeshuyse, Grégoire Vuagniaux, Anne-Mieke Vandamme, Ralf Bartenschlager, Philippe Gallay, Guy Lippens, Johan Neyts |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1844878236 | ||
| 003 | DE-627 | ||
| 005 | 20230710135122.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230509s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pone.0013687 |2 doi | |
| 035 | |a (DE-627)1844878236 | ||
| 035 | |a (DE-599)KXP1844878236 | ||
| 035 | |a (OCoLC)1389805798 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Coelmont, Lotte |e VerfasserIn |0 (DE-588)1288783558 |0 (DE-627)1844879208 |4 aut | |
| 245 | 1 | 0 | |a DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A |c Lotte Coelmont, Xavier Hanoulle, Udayan Chatterji, Carola Berger, Joke Snoeck, Michael Bobardt, Precious Lim, Inge Vliegen, Jan Paeshuyse, Grégoire Vuagniaux, Anne-Mieke Vandamme, Ralf Bartenschlager, Philippe Gallay, Guy Lippens, Johan Neyts |
| 264 | 1 | |c October 27, 2010 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.05.2023 | ||
| 520 | |a DEB025/Debio 025 (Alisporivir) is a cyclophilin (Cyp)-binding molecule with potent anti-hepatitis C virus (HCV) activity both in vitro and in vivo. It is currently being evaluated in phase II clinical trials. DEB025 binds to CypA, a peptidyl-prolyl cis-trans isomerase which is a crucial cofactor for HCV replication. Here we report that it was very difficult to select resistant replicons (genotype 1b) to DEB025, requiring an average of 20 weeks (four independent experiments), compared to the typically <2 weeks with protease or polymerase inhibitors. This indicates a high genetic barrier to resistance for DEB025. Mutation D320E in NS5A was the only mutation consistently selected in the replicon genome. This mutation alone conferred a low-level (3.9-fold) resistance. Replacing the NS5A gene (but not the NS5B gene) from the wild type (WT) genome with the corresponding sequence from the DEB025(res) replicon resulted in transfer of resistance. Cross-resistance with cyclosporine A (CsA) was observed, whereas NS3 protease and NS5B polymerase inhibitors retained WT-activity against DEB025(res) replicons. Unlike WT, DEB025(res) replicon replicated efficiently in CypA knock down cells. However, DEB025 disrupted the interaction between CypA and NS5A regardless of whether the NS5A protein was derived from WT or DEB025(res) replicon. NMR titration experiments with peptides derived from the WT or the DEB025(res) domain II of NS5A corroborated this observation in a quantitative manner. Interestingly, comparative NMR studies on two 20-mer NS5A peptides that contain D320 or E320 revealed a shift in population between the major and minor conformers. These data suggest that D320E conferred low-level resistance to DEB025 probably by reducing the need for CypA-dependent isomerisation of NS5A. Prolonged DEB025 treatment and multiple genotypic changes may be necessary to generate significant resistance to DEB025, underlying the high barrier to resistance. | ||
| 650 | 4 | |a Antiviral Agents | |
| 650 | 4 | |a Cell Line | |
| 650 | 4 | |a Cyclophilin A | |
| 650 | 4 | |a Cyclosporine | |
| 650 | 4 | |a Dose-Response Relationship, Drug | |
| 650 | 4 | |a Hepacivirus | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Isomerism | |
| 650 | 4 | |a Virus Replication | |
| 700 | 1 | |a Hanoulle, Xavier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chatterji, Udayan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Berger, Carola |e VerfasserIn |4 aut | |
| 700 | 1 | |a Snoeck, Joke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bobardt, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lim, Precious |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vliegen, Inge |e VerfasserIn |4 aut | |
| 700 | 1 | |a Paeshuyse, Jan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vuagniaux, Grégoire |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vandamme, Anne-Mieke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bartenschlager, Ralf |d 1958- |e VerfasserIn |0 (DE-588)1058097989 |0 (DE-627)796390509 |0 (DE-576)168706067 |4 aut | |
| 700 | 1 | |a Gallay, Philippe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lippens, Guy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Neyts, Johan |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PLOS ONE |d San Francisco, California, US : PLOS, 2006 |g 5(2010), 10, Artikel-ID e13687, Seite 1-14 |h Online-Ressource |w (DE-627)523574592 |w (DE-600)2267670-3 |w (DE-576)281331979 |x 1932-6203 |7 nnas |a DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A |
| 773 | 1 | 8 | |g volume:5 |g year:2010 |g number:10 |g elocationid:e13687 |g pages:1-14 |g extent:14 |a DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A |
| 856 | 4 | 0 | |u https://doi.org/10.1371/journal.pone.0013687 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230509 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 1058097989 |a Bartenschlager, Ralf |m 1058097989:Bartenschlager, Ralf |d 910000 |d 911700 |e 910000PB1058097989 |e 911700PB1058097989 |k 0/910000/ |k 1/910000/911700/ |p 12 | ||
| 999 | |a KXP-PPN1844878236 |e 4320018435 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Lotte Coelmont, Xavier Hanoulle, Udayan Chatterji, Carola Berger, Joke Snoeck, Michael Bobardt, Precious Lim, Inge Vliegen, Jan Paeshuyse, Grégoire Vuagniaux, Anne-Mieke Vandamme, Ralf Bartenschlager, Philippe Gallay, Guy Lippens, Johan Neyts"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"recId":"1844878236","title":[{"title_sort":"DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A","title":"DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A"}],"origin":[{"dateIssuedDisp":"October 27, 2010","dateIssuedKey":"2010"}],"relHost":[{"part":{"extent":"14","volume":"5","issue":"10","year":"2010","pages":"1-14","text":"5(2010), 10, Artikel-ID e13687, Seite 1-14"},"name":{"displayForm":["Public Library of Science"]},"pubHistory":["1.2006 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"display":"Public Library of Science","role":"isb","roleDisplay":"Herausgebendes Organ"}],"language":["eng"],"recId":"523574592","disp":"DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5APLOS ONE","title":[{"title_sort":"PLOS ONE","title":"PLOS ONE"}],"origin":[{"dateIssuedDisp":"2006-","publisher":"PLOS ; PLoS","dateIssuedKey":"2006","publisherPlace":"San Francisco, California, US ; Lawrence, Kan."}],"id":{"zdb":["2267670-3"],"eki":["523574592"],"issn":["1932-6203"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Schreibweise des Titels bis 2012: PLoS ONE","Gesehen am 20.03.19"]}],"id":{"eki":["1844878236"],"doi":["10.1371/journal.pone.0013687"]},"physDesc":[{"extent":"14 S."}],"person":[{"role":"aut","display":"Coelmont, Lotte","given":"Lotte","family":"Coelmont","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Hanoulle","given":"Xavier","display":"Hanoulle, Xavier","role":"aut"},{"family":"Chatterji","roleDisplay":"VerfasserIn","display":"Chatterji, Udayan","role":"aut","given":"Udayan"},{"roleDisplay":"VerfasserIn","family":"Berger","given":"Carola","display":"Berger, Carola","role":"aut"},{"family":"Snoeck","roleDisplay":"VerfasserIn","display":"Snoeck, Joke","role":"aut","given":"Joke"},{"role":"aut","display":"Bobardt, Michael","given":"Michael","roleDisplay":"VerfasserIn","family":"Bobardt"},{"given":"Precious","role":"aut","display":"Lim, Precious","family":"Lim","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Vliegen","given":"Inge","role":"aut","display":"Vliegen, Inge"},{"roleDisplay":"VerfasserIn","family":"Paeshuyse","given":"Jan","display":"Paeshuyse, Jan","role":"aut"},{"display":"Vuagniaux, Grégoire","role":"aut","given":"Grégoire","family":"Vuagniaux","roleDisplay":"VerfasserIn"},{"family":"Vandamme","roleDisplay":"VerfasserIn","given":"Anne-Mieke","role":"aut","display":"Vandamme, Anne-Mieke"},{"family":"Bartenschlager","roleDisplay":"VerfasserIn","role":"aut","display":"Bartenschlager, Ralf","given":"Ralf"},{"role":"aut","display":"Gallay, Philippe","given":"Philippe","family":"Gallay","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Lippens","given":"Guy","display":"Lippens, Guy","role":"aut"},{"given":"Johan","role":"aut","display":"Neyts, Johan","family":"Neyts","roleDisplay":"VerfasserIn"}],"note":["Gesehen am 09.05.2023"]} | ||
| SRT | |a COELMONTLODEB025ALIS2720 | ||